NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to ...
For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.
WEST LAFAYETTE, Ind. — Purdue University, in collaboration with Eli Lilly and Company and Merck & Co. Inc., announced Friday (Jan. 17) the launch of the Young Institute Pharmaceutical Manufacturing ...
Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...
The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...
On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results